Pricing Log in Create free account
Sunday 18 October 2026 Export CCCC’s income statement to Excel — free account

C4 Therapeutics, Inc.

CCCC Healthcare Biotechnology

C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024. In the quarter to June 2026, revenue grew 2.75%, EPS grew 51.4% and free cash flow grew 86.8%, each against the same quarter a year earlier.

2.77 0.01 −0.36%
Market cap
$342.0M
P/E
0.0×
Fwd P/E
−4.1×
Dividend yield
—
F-score
4/9
Altman Z
−2.16
Beneish M
−2.61
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

C4 Therapeutics, Inc. (CCCC) Business Profile

Updated before January 2025

Company Overview

C4 Therapeutics, Inc. (NASDAQ: CCCC) is a biotechnology company pioneering a new class of targeted protein degradation (TPD) therapies to treat diseases caused by protein dysregulation. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics leverages its proprietary TORPEDO® platform to develop small-molecule drugs that harness the body’s natural protein degradation pathways. The company was co-founded by Dr. James E. Bradner, Dr. Kenneth C. Anderson, and Dr. Nathanael Gray, who are renowned leaders in the fields of chemical biology and oncology. The current leadership team includes Andrew Hirsch, who serves as the President and Chief Executive Officer, and Lauren White, the Chief Financial Officer, among other experienced executives.

C4 Therapeutics has established itself as a leader in the field of protein degradation, a cutting-edge approach to drug discovery and development. The company’s mission is to transform patient care by addressing diseases that were previously considered undruggable.

Core Business Segments

C4 Therapeutics focuses on the development of targeted protein degradation therapies. Its core business segments include:

1. Oncology

C4 Therapeutics is primarily focused on developing therapies for various types of cancer. The company’s lead product candidates include:

  • CFT7455: A novel degrader targeting IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin’s lymphoma.
  • CFT8634: A degrader targeting BRD9 for the treatment of synovial sarcoma and other SMARCB1-deleted cancers.

2. Neurological Disorders

While oncology remains the primary focus, C4 Therapeutics is also exploring the application of its TORPEDO® platform in neurological diseases. The company aims to develop therapies that can degrade disease-causing proteins in neurodegenerative disorders.

3. Strategic Collaborations

C4 Therapeutics has entered into partnerships with leading pharmaceutical companies, including Roche and Biogen, to expand the application of its TORPEDO® platform. These collaborations focus on discovering and developing degraders for specific targets in oncology and other therapeutic areas.

Business Model

C4 Therapeutics operates on a hybrid business model that combines in-house drug development with strategic partnerships. The company generates revenue through:

  • Collaborative Agreements: C4 Therapeutics receives upfront payments, milestone payments, and royalties from its partners, such as Roche and Biogen.
  • Proprietary Drug Development: The company invests in the development of its own pipeline of targeted protein degraders, which it aims to commercialize independently or through partnerships.

The TORPEDO® platform is central to C4 Therapeutics’ business model. This proprietary technology enables the design and development of small-molecule degraders that selectively target disease-causing proteins for degradation. By leveraging this platform, C4 Therapeutics aims to address unmet medical needs across multiple therapeutic areas.

Strategic Direction

C4 Therapeutics is focused on advancing its pipeline of targeted protein degraders and expanding the application of its TORPEDO® platform. Key strategic priorities include:

  • Pipeline Advancement: The company aims to progress its lead candidates, CFT7455 and CFT8634, through clinical trials and regulatory approval.
  • Platform Expansion: C4 Therapeutics is investing in the development of next-generation degraders and exploring new therapeutic areas, including neurological disorders.
  • Sustainability Goals: The company is committed to sustainable practices in its operations and aims to minimize its environmental footprint.
  • Global Expansion: C4 Therapeutics plans to expand its presence in international markets through strategic partnerships and collaborations.

Competitive Landscape

C4 Therapeutics operates in a highly competitive biotechnology sector. Key competitors include:

  • Arvinas, Inc.: A leader in the field of targeted protein degradation, Arvinas develops PROTAC® (Proteolysis Targeting Chimera) degraders.
  • Nurix Therapeutics: Focused on harnessing the body’s natural protein degradation pathways to develop therapies for cancer and immune disorders.
  • Kymera Therapeutics: Another key player in the protein degradation space, Kymera is developing small-molecule degraders for oncology and immune-inflammatory diseases.

C4 Therapeutics differentiates itself through its TORPEDO® platform, which offers unique advantages in terms of selectivity and efficacy.

Risk Factors

C4 Therapeutics faces several risks that could impact its business operations and financial performance:

  • Clinical and Regulatory Risks: The success of the company’s pipeline depends on the outcomes of clinical trials and regulatory approvals, which are inherently uncertain.
  • Market Dependence: C4 Therapeutics relies heavily on the success of its lead candidates, CFT7455 and CFT8634, for future revenue growth.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its drug candidates.
  • Competitive Pressure: The biotechnology sector is highly competitive, and advancements by competitors could impact C4 Therapeutics’ market position.

Recent Developments

C4 Therapeutics has made significant progress in advancing its pipeline and expanding its strategic partnerships. Recent developments include:

  • Clinical Trials: The company initiated Phase 1 clinical trials for CFT7455 and CFT8634, demonstrating its commitment to advancing its pipeline.
  • Partnership with Biogen: C4 Therapeutics expanded its collaboration with Biogen to include additional targets in neurological disorders.
  • Technological Advancements: The company continues to enhance its TORPEDO® platform to improve the selectivity and efficacy of its degraders.

Investment Considerations

Investors considering C4 Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Platform: The TORPEDO® platform positions C4 Therapeutics as a leader in targeted protein degradation.
  • Strong Pipeline: The company has a robust pipeline of drug candidates with significant market potential.
  • Strategic Partnerships: Collaborations with Roche and Biogen provide financial support and access to additional resources.

Risks

  • Early-Stage Company: C4 Therapeutics is still in the clinical development phase and has not yet commercialized any products.
  • High R&D Costs: The company’s focus on innovation requires significant investment in research and development.
  • Regulatory Uncertainty: The approval process for new drugs is complex and time-consuming.

Conclusion

C4 Therapeutics, Inc. is at the forefront of targeted protein degradation, a revolutionary approach to drug discovery and development. With its innovative TORPEDO® platform, strong pipeline, and strategic partnerships, the company is well-positioned to address unmet medical needs in oncology and other therapeutic areas. While the company faces risks associated with clinical development and market competition, its long-term growth prospects remain promising. As C4 Therapeutics continues to advance its pipeline and expand its platform, it has the potential to transform patient care and deliver significant value to investors.